Cat. No.: HY-12808

STF-118804

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

STF-118804 is a highly specific NAMPT inhibitor. STF-118804 activates AMPK and inhibits mTOR pathways. STF-118804 has antitumor activity against pancreatic cancer.

For research use only. We do not sell to patients.

Purity: 99.72%
CAS No.: 894187-61-2
Formula: C₂₅H₂₃N₃O₄S
Molecular Weight:461.54

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

STF-118804 Chemical Structure

CAS No.: 894187-61-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

STF-118804 is a highly specific NAMPT inhibitor. STF-118804 activates AMPK and inhibits mTOR pathways. STF-118804 has antitumor activity against pancreatic cancer^[1]^[2].

All AMPK Isoforms :

All mTOR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
B-ALL	EC₅₀	0.061 μM Compound: 1	Antiproliferative activity against mouse B-ALL BCR-ABL double knockout cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse B-ALL BCR-ABL double knockout cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
B-ALL	EC₅₀	0.072 μM Compound: 1	Antiproliferative activity against mouse B-ALL cells expressing wild type BCR-ABL assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse B-ALL cells expressing wild type BCR-ABL assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
BJ	EC₅₀	2.4938 μM Compound: 1	Antiproliferative activity against human BJ assessed as cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human BJ assessed as cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
K562	EC₅₀	4.6 μM Compound: 1	Antiproliferative activity against human K562 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human K562 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
KOPN-8	EC₅₀	1.23 μM Compound: 1	Antiproliferative activity against human KOPN8 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human KOPN8 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
MV4-11	EC₅₀	3.8 μM Compound: 1	Antiproliferative activity against human MV411 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MV411 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
NALM-6	EC₅₀	0.026 μM Compound: 1	Antiproliferative activity against human NALM6 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human NALM6 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
SUP-B15	EC₅₀	1.1 μM Compound: 1	Antiproliferative activity against human SUP-B15 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SUP-B15 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]
UoC-B1	EC₅₀	>54.98 μM Compound: 1	Antiproliferative activity against human UOCB1 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human UOCB1 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 30611980]

In Vitro

STF-118804 (6.25-25 nM, 72 h) reduces viability and growth of different pancreatic ductal adenocarcinoma cells (PaTu8988t, Panc-1, Su86.86, Panc04.03)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

PaTu8988t, Panc-1, Su86.86, Panc04.03
Concentration:

6.25, 12.5, 25 nM
Incubation Time:

72 h
Result:

Showed more sensitivity to Panc-1 and PaTu8988t cells.

In Vivo

STF-118804 (25 mg/kg, i.p., 3 weeks) demonstrates antitumor activity in an orthotopic mouse model of PDAC (Panc-1)^[1].
STF-118804 (50 mg/kg, s.c., 20 days) improves survival in an orthotopic xenotransplant mouse model of high-risk acute lymphoblastic leukemia^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice (gender not specified, age 4 - 6 weeks) inoculated with Panc-1 cells expressing GFP-luciferase to establish an orthotopic pancreatic cancer model^[1]
Dosage:

25 mg/kg
Administration:

Intraperitoneal injection (i.p.), 3 weeks
Result:

Reduced tumor growth as demonstrated by decreased luminescence, tumor weight and size.
Had no significant toxicity.

Chemical Information

CAS No. 894187-61-2
Appearance Solid
Molecular Weight 461.54
Formula C₂₅H₂₃N₃O₄S
Color White to light yellow
SMILES

O=C(NCC1=CC=CN=C1)C2=CC=C(C3=NC(CS(=O)(C4=CC=C(C)C=C4)=O)=C(C)O3)C=C2
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

PLoS Pathog

Nicotinamide metabolism is essential for Hepatitis C Virus replication and the production of infectious Lipo-Viro-Particles. [Abstract]

2026 Apr 22;22(4):e1014165. PMID: 42018568
bioRxiv

2025 Oct 14.
Patent

US20180263995A1.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (54.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1667 mL

10.8333 mL

21.6666 mL

5 mM

0.4333 mL

2.1667 mL

4.3333 mL

10 mM

0.2167 mL

1.0833 mL

2.1667 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Espindola-Netto JM, et al. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget. 2017 Jun 29;8(49):85054-85067. [Content Brief]

[2]. Matheny CJ, et al. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chem Biol. 2013 Nov 21;20(11):1352-63. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1667 mL	10.8333 mL	21.6666 mL	54.1665 mL
	5 mM	0.4333 mL	2.1667 mL	4.3333 mL	10.8333 mL
	10 mM	0.2167 mL	1.0833 mL	2.1667 mL	5.4166 mL
	15 mM	0.1444 mL	0.7222 mL	1.4444 mL	3.6111 mL
	20 mM	0.1083 mL	0.5417 mL	1.0833 mL	2.7083 mL
	25 mM	0.0867 mL	0.4333 mL	0.8667 mL	2.1667 mL
	30 mM	0.0722 mL	0.3611 mL	0.7222 mL	1.8055 mL
	40 mM	0.0542 mL	0.2708 mL	0.5417 mL	1.3542 mL
	50 mM	0.0433 mL	0.2167 mL	0.4333 mL	1.0833 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

STF-118804

Epigenetics Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) STF-118804

All AMPK Isoforms

All mTOR Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

STF-118804 Related Classifications

HY-12808 Related Classifications